WP3
MSIL2
Biological activity and safety of low dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin‐2 (IL‐2) was
initially discovered and used as a stimulator of effector T lymphocytes
(Teffs), but is now viewed as a very promising immunoregulatory drug having the
capacity to stimulate regulatory T cells (Tregs). At low dose, Il-2 tips the
Treg/Teff balance towards Tregs. Recently, it has been shown that Tregs of MS
patients have reduced proliferative potential. MS-IL2 will assess the safety and biological efficacy
of low-dose IL2 as a Treg inducer in a Relapsing-Remitting Multiple Sclerosis
(RRMS), with the aim to
stimulate Treg and define potential clinical benefits.